Clinical trials
Hepatitis C, Chronic trials in Italy
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
52 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2003 | 3 |
| 2004 | 3 |
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 6 |
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 4 |
| 2011 | 10 |
| 2012 | 9 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 43 |
| Unknown status | 6 |
| Terminated | 2 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hoffmann-La Roche | 15 |
| Gilead Sciences | 5 |
| AbbVie | 4 |
| Debiopharm International SA | 4 |
| Boehringer Ingelheim | 3 |
| Azienda Ospedaliero-Universitaria di Parma | 2 |
| GlaxoSmithKline | 2 |
| University of Modena and Reggio Emilia | 2 |
| University of Turin, Italy | 2 |
| Azienda Ospedaliera San Camillo Forlanini | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hepatitis C, Chronic | 52 |
| Hepatitis C | 20 |
| Hepatitis | 4 |
| Fibrosis | 2 |
| Liver Diseases | 2 |
| Virus Diseases | 2 |
| Acquired Immunodeficiency Syndrome | 1 |
| Cognitive Dysfunction | 1 |
| Digestive System Diseases | 1 |
| Enterovirus Infections | 1 |
Trials
Showing 76 to 52 of 52. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.